ACADIA Pharmaceuticals Inc (ACAD)
Solvency ratios
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt-to-assets ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-capital ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-equity ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial leverage ratio | 1.62 | 1.69 | 1.77 | 1.84 | 1.73 | 1.75 | 1.62 | 1.75 | 1.47 | 1.42 | 1.41 | 1.40 | 1.29 | 1.27 | 1.28 | 1.30 | 1.25 | 1.22 | 1.15 | 1.17 |
ACADIA Pharmaceuticals Inc has consistently maintained a strong solvency position based on its solvency ratios. The Debt-to-assets ratio, Debt-to-capital ratio, and Debt-to-equity ratio have all been consistently at 0.00 from March 31, 2020, to December 31, 2024. This indicates that the company is operating with minimal debt in relation to its assets and capital, which is typically considered favorable as it implies lower financial risk.
The Financial leverage ratio, which measures the company's ability to meet its financial obligations through debt financing, has shown a slight increasing trend over the years, from 1.17 on March 31, 2020, to 1.62 on June 30, 2023, before slightly decreasing to 1.62 on December 31, 2024. While the increase in the financial leverage ratio may indicate a higher reliance on debt financing, the overall ratio remains at a moderate level, suggesting that the company has been able to manage its debt levels effectively.
Overall, based on the solvency ratios analyzed, ACADIA Pharmaceuticals Inc appears to be in a sound financial position with low debt levels and a manageable financial leverage ratio, which bodes well for its long-term financial stability and ability to meet its financial obligations.
Coverage ratios
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interest coverage | — | — | — | — | -8.09 | -12.16 | -8.50 | -10.54 | -33.83 | -71.47 | -219.11 | -436.86 | -288.39 | -189.10 | -123.40 | -68.84 | -43.23 | -29.57 | -22.38 | -22.14 |
ACADIA Pharmaceuticals Inc has experienced a significant decline in its interest coverage ratio over the past few quarters, with the ratio being negative throughout the reported periods. The interest coverage ratio measures a company's ability to cover its interest expenses with its operating income.
The negative values indicate that the company's operating income is insufficient to cover its interest expense. The trend shows a worsening situation as the ratio has been consistently decreasing over the quarters, reaching its lowest point in March 2023. This indicates a higher level of financial risk for the company, as it may struggle to meet its interest obligations with its current level of operating income.
It is worth noting that the interest coverage ratio has improved in the subsequent quarters, turning positive in the quarters ending December 2023 and March 2024. While this is a positive development, it is essential to monitor future trends to assess the company's long-term financial health and ability to meet its interest payment obligations.